Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPercheron Therapeutics Ltd

Percheron Therapeutics Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.003 AUD 0.00(0%)
Last update at 2026-11-06T04:53:00Z
VOLUME
90774
Market Cap
5.95M

Momentum Score

…

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Percheron Therapeutics Ltd is an Australian-listed biotechnology company; publicly available information about its operations and pipeline is limited. The company appears focused on developing therapeutic candidates and could benefit from clinical progress, licensing or partnerships and successful regulatory approvals. Investors may find exposure to potential upside from pipeline advancement attractive, but such exposure is typical of early-stage drug developers.

Key material risks include early-stage development with high clinical and regulatory failure probability, ongoing capital requirements that may dilute shareholders, and limited liquidity on the ASX.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.84M
Revenue Per Share
0.00
Gross Profit TTM
0.66M
Debt / Equity
0.00
ROE
-54.66%
Net Debt
-2.52M
ROCE
-74.63%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -5.49M -16.35M -14.27M -11.38M -5.81M
Net income -4.79M -14.92M -11.92M -11.38M -5.83M
Selling general administrative 2.60M 5.71M 4.04M 3.05M 2.92M
Gross profit -0.22M -0.07M -0.08M - -
Reconciled depreciation 0.22M 0.07M 0.08M 0.10M 0.09M
Ebit -5.62M -16.34M -11.92M -13.34M -7.61M
Ebitda -5.40M -16.27M -11.84M -13.25M -7.52M
Depreciation and amortization 0.22M 0.07M 0.08M 0.10M 0.09M
Operating income -5.62M -16.71M -14.88M -13.34M -7.61M
Other operating expenses 5.62M 16.71M 14.88M 13.34M 7.61M
Interest expense 0.02M 0.01M 0.00M - 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.15M 0.37M 0.62M 0.38M 0.03M
Net interest income 0.13M 0.36M 0.61M 0.38M 0.02M
Income tax expense -0.70M -1.43M -2.35M -0.38M 0.02M
Total revenue - - - 0.38M 0.03M
Total operating expenses 5.40M 16.64M 14.80M 13.34M 7.61M
Cost of revenue 0.22M 0.07M 0.08M - -
Total other income expense net 0.13M 0.36M 0.61M 1.59M 1.80M
Net income from continuing ops -4.79M -14.92M -11.92M -11.38M -5.81M
Net income applicable to common shares - - - -11.38M -5.81M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 8.22M 12.44M 14.53M 12.84M 22.44M
Intangible assets 2.90M - - - -
Other current assets 0.27M - - 1.47M 0.53M
Total liab 0.69M 2.43M 5.17M 2.87M 1.30M
Total stockholder equity 7.53M 10.00M 9.36M 9.98M 21.14M
Other current liab 0.48M - - 1.79M 0.83M
Common stock 63.42M - - 98.26M 98.13M
Capital stock 63.42M 112.05M 109.37M 98.26M 98.13M
Retained earnings -57.97M -103.67M -101.73M -92.29M -80.91M
Other liab - - - 0.01M 0.00M
Cash 2.55M 10.17M 11.87M 10.97M 19.23M
Total current liabilities 0.69M 2.43M 5.15M 2.81M 1.16M
Current deferred revenue - - - -0.09M -0.09M
Net debt -2.52M - - -10.83M -19.01M
Short term debt 0.03M - - 0.09M 0.09M
Short long term debt total 0.03M - - 0.14M 0.23M
Other stockholder equity - - - 4.00M 3.92M
Property plant equipment - - - 0.15M 0.22M
Total current assets 5.29M 12.40M 14.47M 12.69M 22.22M
Net tangible assets - - - 9.98M 21.14M
Short term investments 1.50M - - 10.50M 18.42M
Net receivables 0.96M 0.06M 0.08M 1.66M 1.84M
Inventory - - - 0.00M 0.00M
Accounts payable 0.18M 1.43M 3.73M 1.02M 0.33M
Accumulated other comprehensive income 2.08M - - 4.00M 3.92M
Non currrent assets other - - - -0.15M -0.22M
Non current assets total 2.94M 0.04M 0.06M 0.15M 0.22M
Capital lease obligations 0.03M 0.03M 0.04M 0.14M 0.23M
Long term debt total - - - 0.05M 0.13M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.01M -0.00M -0.03M -0.00M
Change to liabilities - - - 1.76M 0.03M
Total cashflows from investing activities -3.09M -0.01M -0.00M -0.03M -0.00M
Net borrowings - - - -0.09M -0.08M
Total cash from financing activities 1.93M 13.95M 11.02M -0.09M 21.02M
Change to operating activities - - - 0.77M -1.00M
Net income -4.79M -14.92M -11.92M -11.38M -5.81M
Change in cash 1.93M -1.70M 0.90M -8.27M 13.21M
Begin period cash flow 0.62M 11.87M 10.97M 19.23M 6.02M
End period cash flow 2.55M 10.17M 11.87M 10.97M 19.23M
Total cash from operating activities -4.96M -15.64M -10.12M -8.15M -7.81M
Issuance of capital stock 2.17M 14.87M 11.61M - 22.59M
Depreciation 0.22M - - 0.10M 0.09M
Dividends paid - - - - 0.08M
Change to account receivables 0.61M 0.97M -0.83M 0.34M -1.24M
Sale purchase of stock -0.21M -0.86M -0.50M 0.00M -1.49M
Other cashflows from financing activities -0.03M -0.06M -0.09M -0.03M 0.08M
Change to netincome - - - 0.26M 0.12M
Capital expenditures 0.01M 0.01M 0.00M 0.03M 0.00M
Change in working capital -0.74M -2.35M 1.53M 0.34M -1.24M
Stock based compensation - - - 0.21M 0.12M
Other non cash items 0.35M -13.30M 0.28M 3.13M -2.08M
Free cash flow -4.97M -15.65M -10.12M -8.18M -7.81M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PER
Percheron Therapeutics Ltd		 -
-%		 0.00 - 9.35 7.05 0.79 117.93 -4.46
AFP
Aft Pharmaceuticals Ltd		 -
-%		 3.59 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 -
-%		 2.70 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 -
-%		 0.06 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.40 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

Percheron Therapeutics Ltd

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Collins Place, Melbourne, VIC, Australia, 3000

61 3 9827 8999

https://percherontx.com

Name Title Year Born
Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD CEO, MD & Director NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Joint Company Sec. 1959
Dr. George Tachas Director of Drug Discovery & Patents NA
Ms. Nuket Desem Director of Clinical and Regulatory affairs NA
Dr. Anthony Filippis Chief Commercial Officer NA
Ms. Alicia Mellors Joint Company Sec. NA
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA CEO, MD & Director 1973
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Joint Company Secretary 1959
Dr. Anthony Filippis Chief Operating Officer NA
Ms. Alicia Mellors Joint Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…